Key result
Ticagrelor linked to lower post-PCI major cardiovascular events vs clopidogrel in CYP2C19 intermediate metabolizers without excess bleeding.
Why the study?
The efficacy and safety of different antiplatelet therapies for stable angina patients with complicated left main coronary artery lesions and intermediate metabolizer CYP2C19 undergoing PCI were unclear.
Cohort (n=152)
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate the efficacy and safety of different antiplatelet therapies for stable angina patients with complicated left main coronary artery lesions and intermediate metabolizer Cytochrome P450 2C19 gene (CYP2C19) undergoing PCI. METHODS: =152) according to the different antiplatelet treatment programs. Both groups were given aspirin 300 mg and clopidogrel 300 mg orally before PCI; the ticagrelor group were given the maintenance dose of ticagrelor (90 mg orally, twice a day) after PCI, while those in clopidogrel group were clopidogrel 75 mg orally (once a day) after PCI; both groups were given the maintenance dose of aspirin (100 mg orally, once a day)after PCI. The major adverse cardiovascular events (MACE) were observed within 12 months after PCI. There were also no significant differences between the two groups in bleeding. CONCLUSIONS: For stable angina patients with complicated left main coronary artery lesions and intermediate metabolizer CYP2C19 gene, aspirin combined with ticagrelor antiplatelet therapy after PCI is effective, the effect of ticagrelor is better than clopidogrel on MACE, and ticagrelor does not seem to increase the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Xiaofang Zheng (2020) conducted a cohort in Stable angina with left main coronary artery lesions (n=152). Ticagrelor vs. Clopidogrel 75 mg once a day orally (maintenance) was evaluated on Major adverse cardiovascular events (MACE). Ticagrelor combined with aspirin after PCI was more effective than clopidogrel at reducing major cardiovascular events without increasing bleeding risk in stable angina patients with intermediate metabolizer CYP2C19.
Synapse has enriched 10 related papers. Consider them for comparative context: